Bank of New York Mellon Corp Has $1.01 Million Stake in Puma Biotechnology, Inc. (NASDAQ:PBYI)

Bank of New York Mellon Corp increased its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 63.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 308,997 shares of the biopharmaceutical company’s stock after purchasing an additional 120,104 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.64% of Puma Biotechnology worth $1,007,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in shares of Puma Biotechnology in the first quarter worth $57,000. Crestline Management LP increased its position in Puma Biotechnology by 6.5% in the 4th quarter. Crestline Management LP now owns 34,774 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 2,135 shares during the last quarter. Lazard Asset Management LLC raised its stake in shares of Puma Biotechnology by 5,129.0% during the 1st quarter. Lazard Asset Management LLC now owns 49,466 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 48,520 shares in the last quarter. Jump Financial LLC lifted its holdings in shares of Puma Biotechnology by 131.7% during the 4th quarter. Jump Financial LLC now owns 57,200 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 32,510 shares during the last quarter. Finally, EntryPoint Capital LLC bought a new stake in shares of Puma Biotechnology in the 1st quarter valued at approximately $329,000. 61.29% of the stock is owned by hedge funds and other institutional investors.

Puma Biotechnology Price Performance

Shares of NASDAQ:PBYI opened at $2.60 on Friday. The stock has a market capitalization of $125.42 million, a P/E ratio of 7.88 and a beta of 1.09. The business has a 50-day moving average of $3.05 and a two-hundred day moving average of $3.93. Puma Biotechnology, Inc. has a fifty-two week low of $2.13 and a fifty-two week high of $7.73. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.32 and a quick ratio of 1.23.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. Puma Biotechnology had a return on equity of 18.36% and a net margin of 4.01%. The firm had revenue of $47.10 million during the quarter, compared to analyst estimates of $43.99 million. During the same period in the previous year, the company earned $0.05 EPS. On average, equities research analysts predict that Puma Biotechnology, Inc. will post 0.25 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Michael Patrick Miller sold 23,358 shares of Puma Biotechnology stock in a transaction on Monday, August 12th. The shares were sold at an average price of $3.49, for a total value of $81,519.42. Following the transaction, the director now owns 47,000 shares in the company, valued at approximately $164,030. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Puma Biotechnology news, Director Michael Patrick Miller sold 23,358 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $3.49, for a total value of $81,519.42. Following the sale, the director now owns 47,000 shares of the company’s stock, valued at approximately $164,030. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Alan H. Auerbach sold 21,920 shares of Puma Biotechnology stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $3.70, for a total value of $81,104.00. Following the completion of the transaction, the chief executive officer now directly owns 7,063,515 shares in the company, valued at $26,135,005.50. The disclosure for this sale can be found here. In the last three months, insiders sold 82,263 shares of company stock valued at $286,469. Company insiders own 23.70% of the company’s stock.

Analyst Ratings Changes

PBYI has been the topic of several recent research reports. StockNews.com lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Puma Biotechnology in a report on Friday, August 2nd.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.